Document is current
Any future updates will be listed below
-
Authors
Lau, William C.
Lebwohl, Mark G.
- License Information
-
More Information
Article History
Received: 22 September 2025
Revised: 3 February 2026
Accepted: 18 February 2026
First Online: 5 March 2026
Declarations
:
: Author Lau does not have any conflicts of interest to disclose. Author Lebwohl is an employee of Mount Sinai and receives research funds from: Abbvie, Arcutis, Avotres, Boehringer Ingelheim, Cara therapeutics, Clexio, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen, Pfizer, Sanofi-Regeneron, and UCB, and is a consultant for Almirall, AltruBio Inc., Apogee, Arcutis, Inc., AstraZeneca, Atomwise, Avotres Therapeutics, Boehringer-Ingelheim, Bristol-Myers Squibb, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences, Dermsquared, Evommune, Inc., Facilitation of International Dermatology Education, Forte biosciences, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda, Trevi, and Verrica.
: None declared.
